MX362752B - Formas mórficas de ésteres de hexadeciloxipropil-fosfonato. - Google Patents

Formas mórficas de ésteres de hexadeciloxipropil-fosfonato.

Info

Publication number
MX362752B
MX362752B MX2016006241A MX2016006241A MX362752B MX 362752 B MX362752 B MX 362752B MX 2016006241 A MX2016006241 A MX 2016006241A MX 2016006241 A MX2016006241 A MX 2016006241A MX 362752 B MX362752 B MX 362752B
Authority
MX
Mexico
Prior art keywords
hexadecyloxypropyl
phosphonate esters
morphic forms
ester compounds
phosphonate ester
Prior art date
Application number
MX2016006241A
Other languages
English (en)
Other versions
MX2016006241A (es
Inventor
Wendell Ware Roy
Leigh Downey Aaron
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of MX2016006241A publication Critical patent/MX2016006241A/es
Publication of MX362752B publication Critical patent/MX362752B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

La descripción describe métodos de síntesis de compuestos de éster de fosfonato. Los métodos de acuerdo a la descripción permiten la preparación a gran escala de compuestos de éster de fosfonato que tienen alta pureza y estabilidad. También se describen formas mórficas de compuestos de éster de fosfonato.
MX2016006241A 2013-11-15 2014-10-10 Formas mórficas de ésteres de hexadeciloxipropil-fosfonato. MX362752B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904857P 2013-11-15 2013-11-15
PCT/US2014/060185 WO2015073148A1 (en) 2013-11-15 2014-10-10 Morphic forms of hexadecyloxypropyl-phosphonate esters

Publications (2)

Publication Number Publication Date
MX2016006241A MX2016006241A (es) 2016-09-06
MX362752B true MX362752B (es) 2019-02-07

Family

ID=52472937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006241A MX362752B (es) 2013-11-15 2014-10-10 Formas mórficas de ésteres de hexadeciloxipropil-fosfonato.

Country Status (15)

Country Link
US (8) US8962829B1 (es)
EP (1) EP2999476B1 (es)
JP (3) JP6150949B2 (es)
KR (3) KR101812433B1 (es)
CN (2) CN105899215A (es)
AU (3) AU2014349103B2 (es)
BR (1) BR112016010862B1 (es)
CA (1) CA2929593C (es)
DK (1) DK2999476T3 (es)
EA (1) EA031861B1 (es)
ES (1) ES2685819T3 (es)
IL (3) IL302520A (es)
MX (1) MX362752B (es)
UA (1) UA116825C2 (es)
WO (1) WO2015073148A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011295937B2 (en) * 2010-08-31 2015-04-16 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
JP6150949B2 (ja) 2013-11-15 2017-06-21 キメリックス インコーポレイテッド ヘキサデシルオキシプロピル−ホスホン酸エステルの形態型
ES2915381T3 (es) 2014-09-15 2022-06-22 Univ California Análogos de nucleótidos
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
US20170368082A1 (en) * 2016-06-28 2017-12-28 Chimerix, Inc. Formulations of brincidofovir
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002511A1 (en) 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
WO2000024763A1 (en) * 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
US20020022659A1 (en) * 2000-07-19 2002-02-21 Harris Gregory D. Crystalline and salt forms of an HIV protease inhibitor
US20070021430A1 (en) * 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
US7511051B2 (en) * 2004-07-02 2009-03-31 University Of Southern California Cidofovir peptide conjugates as prodrugs
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
US20070003608A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2012799B1 (en) * 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2008007392A2 (en) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
AU2008246195B2 (en) 2007-04-27 2014-06-05 Emergent Biodefence Operations Lansing Llc Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101143879A (zh) * 2007-11-08 2008-03-19 上海交通大学 含硫无环核苷膦酸类似物及其制备方法
US20110009368A1 (en) * 2007-12-12 2011-01-13 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
EP2493479A4 (en) 2009-10-30 2013-04-17 Chimerix Inc METHOD FOR THE TREATMENT OF VIRUS DISEASES
WO2011100698A2 (en) * 2010-02-12 2011-08-18 Chimerix, Inc. Methods of treating viral infection
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011295937B2 (en) * 2010-08-31 2015-04-16 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
CA2853720A1 (en) * 2011-10-26 2013-05-02 Chimerix, Inc. Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
WO2013163509A1 (en) * 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
US20140011769A1 (en) * 2012-07-03 2014-01-09 Chimerix, Inc. Methods of Treating Retroviral Infections and Related Dosage Regimes
JP6150949B2 (ja) * 2013-11-15 2017-06-21 キメリックス インコーポレイテッド ヘキサデシルオキシプロピル−ホスホン酸エステルの形態型
CA2932423A1 (en) * 2013-12-05 2015-06-11 Chimerix, Inc. Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
US20170368082A1 (en) * 2016-06-28 2017-12-28 Chimerix, Inc. Formulations of brincidofovir

Also Published As

Publication number Publication date
US11066373B2 (en) 2021-07-20
KR101812433B1 (ko) 2017-12-26
US20180086721A1 (en) 2018-03-29
WO2015073148A1 (en) 2015-05-21
EA031861B1 (ru) 2019-03-29
US9371344B2 (en) 2016-06-21
UA116825C2 (uk) 2018-05-10
US10487061B2 (en) 2019-11-26
ES2685819T3 (es) 2018-10-11
BR112016010862B1 (pt) 2022-11-29
DK2999476T3 (en) 2018-09-03
JP6150949B2 (ja) 2017-06-21
JP2017200919A (ja) 2017-11-09
AU2014349103A1 (en) 2016-06-16
CN111777639A (zh) 2020-10-16
CA2929593C (en) 2020-03-10
US20200095208A1 (en) 2020-03-26
US9862687B2 (en) 2018-01-09
IL302520A (en) 2023-07-01
IL245576A0 (en) 2016-06-30
US20160264531A1 (en) 2016-09-15
BR112016010862A8 (pt) 2020-04-22
EA201691006A1 (ru) 2017-02-28
AU2014349103B2 (en) 2017-01-12
KR20170143010A (ko) 2017-12-28
BR112016010862A2 (pt) 2017-08-08
AU2017203315A1 (en) 2017-06-08
MX2016006241A (es) 2016-09-06
US8962829B1 (en) 2015-02-24
EP2999476A1 (en) 2016-03-30
EP2999476B1 (en) 2018-08-08
KR20170143009A (ko) 2017-12-28
JP6401820B2 (ja) 2018-10-10
JP2016538326A (ja) 2016-12-08
US11912667B2 (en) 2024-02-27
KR20160078500A (ko) 2016-07-04
CA2929593A1 (en) 2015-05-21
US20220144782A1 (en) 2022-05-12
JP2017200920A (ja) 2017-11-09
IL245576B (en) 2022-03-01
US10112909B2 (en) 2018-10-30
US20150210724A1 (en) 2015-07-30
CN105899215A (zh) 2016-08-24
US20240217938A1 (en) 2024-07-04
EP2999476A4 (en) 2016-04-13
US20190016687A1 (en) 2019-01-17
IL279291A (en) 2021-01-31
AU2017202386A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
MX362752B (es) Formas mórficas de ésteres de hexadeciloxipropil-fosfonato.
GB2518547B (en) Method for the preparation of high purity lignin
WO2014164533A8 (en) Methods of stereoselective synthesis of substituted nucleoside analogs
EP3077399A4 (en) Methods useful in the synthesis of halichondrin b analogs
EP3047030A4 (en) A high yield route for the production of compounds from renewable sources
PL2693881T3 (pl) Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
SI2984490T1 (sl) Metode proizvodnje derivatov omega hidroksilirane maščobne kisline
IN2015DN02376A (es)
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
ZA201505457B (en) Process for the preparation of succinic acid ester
EP3048172A4 (en) Method for producing l-amino acid from seaweed-derived biomass
IN2013MU03070A (es)
ZA201505352B (en) Process for the preparation of succinic acid ester
EP3402786A4 (en) METHOD FOR THE PRODUCTION OF EPOXYED FATTY ACID ALKYL ESTERS AS SOFTWARE MAKERS
GB2528618B (en) Chromatographic process for the production of highly purified polyunsaturated fatty acids
ZA201603839B (en) Process for the production of synthesis gas
FR3003872B1 (fr) Procede de stabilisation des metabolites sensibles a l'oxydation produits par les microalgues du genre chlorella
MX361673B (es) Procedimiento para la preparación de intermediarios de ácido borónico.
IN2014DN07498A (es)
IN2013MU02748A (es)
GB2503103B8 (en) Process for the production of fatty acid esters
IN2013MU02612A (es)
HUP1200570A2 (en) Process for the incorporation of micro- and mesoelements and other compounds having positive effect on the yield into the soil
MX2016001100A (es) Proceso mejorado para preparar la forma cristalina iv del posaconazol.

Legal Events

Date Code Title Description
FG Grant or registration